ADT alone, n = 23 | ADT + cryosurgery, n = 20 | p | |
---|---|---|---|
Age (years), mean ± SD | 68.7 ± 7.2 | 70.3 ± 7.5 | 0.479 |
≤60, n (%) | 3 (13.0%) | 2 (10%) | 0.716 |
60‑70, n (%) | 14 (60.9%) | 12 (60%) | |
> 70, n (%) | 6 (26.1%) | 6 (30%) | |
PSA (ng/ml), mean ± SD | 84.16 ± 27.45 | 84.83 ± 31.77 | 0.074 |
Biopsy Gleason score, n (%) | |||
≤ 6 | 1 (4.3%) | 2 (10%) | 0.615 |
7 | 8 (34.8%) | 7 (35%) | |
≥ 8 | 14 (60.9%) | 11 (55%) | |
Prostate volume (ml), mean ± SD | 42.00 ± 3.73 | 42.30 ± 4.24 | 0.806 |
Clinical T stage, n (%) | |||
≤cT2b | 8 (34.8%) | 5 (25%) | 0.555 |
cT2c | 10 (43.5%) | 10 (50%) | |
cT3a | 5 (21.7%) | 5 (25%) | |
Lymph nodes status, n (%) | |||
N0 | 18 (78.3%) | 15 (75%) | 0.801 |
N1 | 5 (21.7%) | 5 (25%) | |
Bone metastases count, n (%) | |||
≤ 3 | 10 (43.5%) | 11 (55%) | 0.451 |
> 3 | 13 (56.5%) | 9 (45%) | |
CTCs count, median (IQR) | 6 (3‑7) | 4 (3‑6) | 0.475 |